Press Releases

Anton Henssen of the ECRC has been awarded the Kind Philipp Award for Pediatric Oncology Research for his study of ring-shaped DNA and its significance in the development of childhood neuroblastoma. A publication in the scientific journal Nature Genetics was decisive for this award.

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults.

On January 1, 2021, the Berlin Institute of Health (BIH ) has become the translational research unit of Charité – Universitätsmedizin Berlin and will then form – alongside the hospital and the medical faculty – Charité’s third pillar.

Enlarged ventricles in the brains of people with multiple sclerosis were previously considered a sign of tissue loss. But a team at the MDC and ECRC demonstrated that this expansion often recedes. A study published in JCI Insight now shows that the process observed in mice is transferable to humans.

The Berlin biotech start-up T-knife, a spin-off from the MDC together with Charité, has secured investments totaling €66 million. Four venture capital funds committed to the financing in early August. T-knife develops new cancer treatments using modified immune system T cells.

After more than 40 years, several teams at the MDC and ECRC have now made a breakthrough discovery with the help of two animal models: they have proven that an altered gene encoding the enzyme PDE3A causes an inherited form of high blood pressure. This could lead to new concepts for the treatment of hypertension.

The LabHive digital platform aims to provide necessary resources to diagnostic centres to enable more tests for SARS-CoV-2. Tobias Opialla from the MDC is one of 15 volunteers who has been involved in the project since the #WirvsVirus Hackathon organized by the German government.

Researchers at the ECRC have successfully used RNA molecules to treat a dangerous pregnancy disorder called preeclampsia. They were able to alleviate common symptoms of the disorder, like maternal high blood pressure and fetal undernutrition, with virtually no side effects.

Strategies for treating multiple sclerosis have so far focused primarily on T and B cells. A group of MDC researchers has now unveiled a new approach in Nature Immunology – one that seeks to increase treatment effectiveness by selectively targeting another type of immune cell called monocytes.

Thomas Blankenstein receives an ERC Advanced grant for cancer research. The scientist wants to find out if T cells control the development of cancer by a process called immunosurveillance. For this purpose he now proposes a new research model.